Jazz Pharmaceuticals officer reports 7,159-share sale under 10b5-1

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc executive Robert Iannone, EVP, Global Head of R&D & CMO, reported a stock sale in a Form 4 filing. On 11/17/2025, he sold 7,159 ordinary shares of JAZZ at $168.26 per share in a transaction carried out under a pre-arranged Rule 10b5-1 trading plan. After this sale, he beneficially owned 72,628 ordinary shares. A footnote notes that he had previously acquired 166 ordinary shares on May 30, 2025 under a Section 423 Employee Stock Purchase Plan.

Insider Trade Summary

Net Seller: 7,159 shares ($1,204,573)

Net Sell 1 txn

Insider Iannone Robert

Role EVP, Global Head of R&D & CMO

Sold 7,159 shs ($1.20M)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	7,159	$168.26	$1.20M

Holdings After Transaction: Ordinary Shares — 72,628 shares (Direct)

Footnotes (1)

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Reporting Person acquired 166 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 30, 2025.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Iannone Robert

(Last) (First) (Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4 L2

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Global Head of R&D & CMO

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	11/17/2025		S(1)		7,159	D	$168.26	72,628(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

2. The Reporting Person acquired 166 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 30, 2025.

	By: /s/Adam Guttmann, as attorney in fact For: Robert Iannone	11/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did JAZZ executive Robert Iannone report?

In a Form 4, Robert Iannone, EVP, Global Head of R&D & CMO of Jazz Pharmaceuticals plc, reported selling 7,159 ordinary shares of JAZZ on 11/17/2025.

At what price were the JAZZ shares sold in the reported Form 4 transaction?

The Form 4 shows that 7,159 ordinary shares of JAZZ were sold at a price of $168.26 per share on 11/17/2025.

Was the JAZZ insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states that the transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

How many JAZZ shares does Robert Iannone beneficially own after the transaction?

Following the reported sale, the Form 4 lists 72,628 ordinary shares of Jazz Pharmaceuticals plc as beneficially owned by Robert Iannone.

What prior share acquisition by the JAZZ executive is referenced in the Form 4?

A footnote notes that the reporting person acquired 166 ordinary shares on May 30, 2025 under a Section 423 Employee Stock Purchase Plan.

What is Robert Iannone’s role at Jazz Pharmaceuticals plc?

The Form 4 identifies the reporting person as an officer of Jazz Pharmaceuticals plc with the title EVP, Global Head of R&D & CMO.